Researchers from the National University of Singapore (NUS) have developed a new cancer testing method that makes regular monitoring more affordable.

The new test, dubbed the Heatrich-BS assay, heats the clinical samples to isolate cancer-specific signatures found in a patient’s blood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The research team discovered the new method, which discards the non-informative sections of a patient’s DNA and targets where most cancer-specific biomarkers are concentrated instead.

DNA is comprised of molecules called nucleotides: namely adenine (A), thymine (T), guanine (G) and cytosine (C).

NUS said that cancer-specific signatures tend to be concentrated in genome areas that have high repetitions of C and G nucleotides, known as CpG islands.

NUS assistant professor Cheow Lih Feng said: “We were performing some unrelated experiments, and one of our researchers heated a sample.”

He said that the team accidentally discovered that the heat destroyed the non-informative sections of the genome, however, it left CpG island largely intact.

This helped the team to sequence the residual genome and identify the presence of cancer for a minute fraction of the average market price.

Cheow added: “We are getting a much more sensitive assay at almost the same costs as compared to simple protein biomarker tests. Our method really concentrates on sequencing these regions that matter the most.”

The new Heatrich-BS assay has been evaluated at the National Cancer Centre in Singapore, where it was used to monitor colorectal cancer patients.

The researchers’ team compared the results of the patients’ blood analysis with their CT scans, which showed the patients’ tumour size.

They found a high correlation between the size of the patient’s tumours over time and how much cancer-specific DNA was detected in their blood sample.

Cheow also said that the new method can work globally across all cancer types, as they all demonstrate the property of enriching CpG islands with biomarkers that are cancer-specific.